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ABSTRACT
Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs), one of the most commonly used medica-
tions worldwide, are frequently associated with gastrointestinal adverse events. Primary care physicians 
often face the challenge of achieving adequate pain relief with NSAIDs, while keeping their adverse events 
to a minimum. This is especially true when long-term use of NSAIDs is required such as in patients with 
osteoarthritis and rheumatoid arthritis.  To help primary care physicians deal with such challenges more 
effectively, a panel of expert gastroenterologists came together with the aim of developing practice recom-
mendations. 
Methods: A modified ‘Delphi’ process was used to reach consensus and develop practice recommenda-
tions. Twelve gastroenterologists from nine countries provided their expert inputs to formulate the recom-
mendations. These recommendations were carefully developed taking into account existing literature, 
current practices, and expert opinion of the panelists. 
Results: The expert panel developed a total of fifteen practice recommendations. Following are the key 
recommendations: NSAIDs should be prescribed only when necessary; before prescribing NSAIDs, 
associated modifiable and non-modifiable risk factors should be considered; H. pylori infection should be 
considered and treated before initiating NSAIDs; patients should be properly educated regarding NSAIDs 
use; patients who need to be on long-term NSAIDs should be prescribed a gastroprotective agent, preferably 
a proton pump inhibitor and these patients should be closely monitored for any untoward adverse events.
Conclusion/clinical significance: These practice recommendations will serve as an important tool for 
primary care physicians and will guide them in making appropriate therapeutic choices for their patients.
Keywords: Gastropathy, Gastroprotective agents, Non-prescription drugs, Nonsteroidal Anti-inflammatory 
Agents, Proton pump inhibitor.
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BACKGROUND
Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
used by over 30 million people daily across the globe.1 
The use of NSAIDs has become widespread due to the 
availability of these agents both as prescription and 
as over-the-counter (OTC) medicines.2 Even though 
NSAIDs have proven efficacy in managing pain, fever, 
and inflammation, they are frequently associated with 
several untoward adverse events (AEs).3 While NSAIDs 
are also associated with renal (fluid retention, hyper-
kalemia, secondary hypertension) and cardiovascular 
(vascular events, hypertension) AEs, the most common 
are gastrointestinal (GI) complications, which include-
gastritis, ulcers, perforation, and enteropathy.3,4A study 
from Denmark reported an increase in the prevalence of 
NSAID-related peptic ulcers from 39% in 1993 to 53% in 
2002.5 Further, the point prevalence of GI complications 
related to NSAID exposure in the Indian subcontinent in 
the year 2014 was found to be 30%.6 Overall, mortality in 
patients suffering from an upper gastrointestinal (UGI) 
bleed or perforation related to NSAIDs use is estimated 
to be about 1 in 5.7 Additionally, the prevalence of gas-
troduodenal ulcers in patients taking low-dose aspirin 
(LDA) is about 10%.8 
The NSAID-induced gastropathy (NIG) develops at 
doses that inhibit prostaglandin production, enhance 
gastric motility, and increase mucosal permeability. 
This results in neutrophil infiltration and free radical 
production, and eventually mucosal lesions.9 Risk factors 
include increasing age, the presence of comorbidities 
especially a history of peptic ulcer disease, liver cirrhosis, 
and cardiovascular disease. Long-term use of NSAIDs, 
Helicobacter pylori (H. pylori) infection, smoking, chronic 
alcohol abuse, and concomitant use of other medications 
increase the risk of developing NIG.3,10-13
The NSAIDs have remained the first-line for control-
ling pain and inflammation particularly in patients with 
osteoarthritis (OA). Complete withdrawal from NSAIDs 
is not always practical, particularly in patients with 
chronic musculoskeletal disorders. Therefore, it is impor-
tant that clinicians prescribe NSAIDs wiselyto ensure 
maximum benefits and minimize AEs. All healthcare 
practitioners, particularly primary care physicians (PCP) 
can reduce the risk of NIG by careful patient assessment 
and identification of the risk factors before prescribing 
an NSAID, educating patients against the addition of 
OTC NSAIDs, using selective cyclooxygenase-2 (COX-2) 
inhibitors as first-line medications where appropriate,and 
co-therapy with a gastroprotective agent (GPA).1,3,9
Several international and regional guidelines have 
been developed to manage NSAID-induced GI complica-
tions.10-17 However, none specifically focus on manage-
ment of NIG highlighting the need for a comprehensive 
clinical guidelineto guide PCPs in the management of 
NIG, particularly in resource-limited regions of the world. 
This article presents practice recommendations primarily 
targeted towards primary care providers, for prevention, 
early detection, and management of NIG formulated at 
a meeting held in Dubai, UAE on December 1st, 2016.   
OBJECTIVE
The objective of this consensus meeting was to identify 
the advances in disease management and the opportu-
nitiesfor prevention and management of NIG in nine 
nations. Further, we attempted to develop definitive clini-
cal practice guidelines for the management of patients 
with NIG based on the existing literature, real-world 
evidence, and evidence-based practice.
Ameeting was held before the International Con-
gress of GI Experts, Gastrosphere 2.0 (in Dubai, UAE) 
in association with the healthy stomach initiative (HSI). 
The committee of experts from nine nations was named 
the ICON-G group. Expert representatives proposed 
recommendations for use by PCPs and internists in the 
prevention, identification, and management of NIG.   
METHODS
A modified Delphi consensus process (Fig. 1) was imple-
mented to develop the recommendations.18,19 Literature 
was searched to provide evidence, and recommendations 
were developed by combining evidence-based and expert 
consensus-based approach. A comprehensive metho-
dology and transparency in reporting were adopted to 
develop these clinical practice recommendations.  
The process was conducted in two phases. Phase 
one included an online survey and literature search. 
The online survey(on online portal survey monkey.
com)  included twenty questions to establish the current 
clinical practice in the nine countries. The responses 
collected from the survey were then used to quantify 
theknowledgeand practice gap in each of the countries.  
An electronic literature search was conducted in 
PubMed and MEDLINE. The search strategy was devel-
oped by combining Medical Subject Headings (MeSH) 
and free-text keywords using Boolean operators (‘OR’ 
and ‘AND’). Keywords used were “nonsteroidal anti-
inflammatory drugs”, “NSAIDS”, “gastropathy”, “gastri-
tis”, “ulcers”, “gastric bleeding”, “gastric complications”, 
and “gastroprotective agents”. Relevant literature from 
published clinical studies, narrative reviews, system-
atic reviews, and meta-analyses was collected through 
September 2016. No additional filters were used during 
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the search. An extensive manual search of literature 
references was also done, and relevant articles retrieved. 
Several published international and regional clinical 
practice guidelines on the management of GI complica-
tions were also retrieved.10-17All the available literature 
and evidence were collated and developed into practice 
recommendations. These were discussed at the meeting 
and categorized according to the level of evidence.
In phase two, core-committee of ICON-G members 
comprising of a chairperson and twelve expert gastroen-
terologists from Russia, India, Romania, Ukraine, South 
Africa, Kazakhstan, Belarus, Uzbekistan, and Myanmar, 
with knowledge and experience of NSAID-induced GI 
injury, was formed. A pre-meeting draft depicting the 
purpose of the guidelines, the target patient popula-
tion, clinical outcomes of interest, key features of the 
systematic literature review, and a proposed timeline for 
guideline completion was shared with all panel members. 
An advisory board meeting chaired by Professor Richard 
Hunt was conducted with the core-committee of ICON-G 
on December 1st, 2016 in Dubai (UAE), to discuss and 
establish the process for the consensus guideline devel-
opment.
On December 3rd, 2016, the members of Consensus 
Group (i.e., members of core-committee of ICON-G 
together with delegates attending the International Con-
gress of GI Experts) discussed and rated their agreement 
for each recommendation on a four-point Likert scale. 
Open discussion was conducted for each recommenda-
tion, considering evidence and rationale. Voting then took 
place. About 60% of the voters were gastroenterologists, 
and 40% were general physicians , with extensive expe-
rience of delivering patient care across a wide range of 
specialties relevant to primary care. The core-committee 
determined the strength of agreement for each recom-
mendation as follows:
• Strong Consensus: If ≥90% of respondents rated the 
recommendation as “strongly agree” and/or “agree”
• Consensus: If ≥80% and <90% of respondents ratedthe 
recommendation as “strongly agree” and/or “agree”
• No Consensus: If <80% of the respondents rated the 
recommendation as “strongly agree” and/or “agree”
PRACTICE RECOMMENDATIONS
Practice Recommendation 1  
The NSAID prescription is associated with a high-risk 
of NIG.
(Consensus: Vote; strongly agree 76%, agree 24%) 
Rationale
Studies have shown that NSAIDs are associated with 
gastropathy irrespective of the duration of use.
The evidence study (N = 4144) was the largest pro-
spective study of the real-life management of European 
patients treated with NSAIDs for rheumatic diseases, who 
wereat an increased GI risk due to advanced age (≥60 
years), history of peptic ulcer, or concomitant therapy 
(corticosteroids, anticoagulants).20 The study found that 
NSAIDs were associated with an incidence of 18.5 per 
100 person-years for uncomplicated GI events and 0.7 
per 100 person-years for complicated GI events. During 
a median follow-up of 6 months, UGI events (12%) were 
more common than the lower GI events (1%).20
A systematic review (N = 19841) reported that the 
risk of developing serious NSAID-related GI events is 
essentially constant over time.21 A large autopsy series 
on patients with a history of NSAID use found a slightly 
higher number of nonspecific ulcers in the small intestine 
in long-term NSAID users, and a slightly higher number 
ofgastric ulcersin short-term NSAID users when com-
pared to long-term users.22
A nested case-control study found that, compared 
to non-users, current NSAID users are at a higher risk 
of developing serious UGI complications by a factor of 
Fig. 1: Modified Delphi protocol for consensus development
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3.7 [95% confidence interval (CI ),  3.1–4.3], and selective 
COX-2 inhibitors by a factor of 2.6 (95% CI, 1.9–3.6).23  This 
study also foundthat short- and long-term NSAIDs use 
was associated with a similar risk of UGI complications. 
Similar findings were reported inother meta-analyses 
where the relative risk (RR) of serious GI complica-
tions was found to be 3 to 4 fold higher in NSAID users 
compared with non-users irrespective of the duration 
of use.24-26      
A multicenter study (N = 187) reported a high point 
prevalence rate for ulcers (10.7%) and erosions (63.1%) 
in patients taking LDA. After a follow-up of 3 months 
(N = 113) the incidence of ulcers anderosions was 7.1% 
and 60.2%, respectively, suggesting ulcers developed in 
almost 1 in 10 LDA users.27A meta-analysis (N~66000) to 
assess the incidence of GI hemorrhage associated with 
aspirin therapy showed that long-term (≥12 months) 
aspirin treatment was associated with a significant 
increase in the incidence of GI bleeding. Bleeding was 
reported in 2.47% of patients taking aspirin compared 
with 1.42% taking a placebo [odds ratio (OR) 1.68; 95% 
CI,1.51–1.88].28
Practice Recommendation 2
All NSAIDs, irrespective of their route of administration, 
have the potential to NIG.
(Consensus: Vote; strongly agree 64%, agree 34%, disagree 
2%) 
Rationale
Although topical NSAIDs are generally safer than oral 
NSAIDs withfewer severe GI AEs, 17.5% of patients 
receiving topical NSAIDs in onestudy reported systemic 
AEs. Topical NSAIDs potentiated warfarin in five cases, 
leading to GI bleeding in one case.29 
A meta-analysis comparing the safety profile of dif-
ferent types of NSAIDs confirmed the variability inRR 
among various NSAIDs.30 Irrespective of the type and 
formulation, all NSAIDs were associated with GI AEs. 
The lowest RR was observed with aceclofenac, celecoxib, 
and ibuprofen, and the highest with piroxicam, ketoro-
lac, and azapropazone. Rofecoxib, sulindac, diclofenac, 
meloxicam, nimesulide, ketoprofen, tenoxicam, naproxen, 
indomethacin, and diflunisal were associated with mod-
erate risks.30 In another meta-analysis, nabumetone was 
associated with a very low GI risk when compared to 
other NSAIDs (p = 0.007).31    
Somenovel NSAID formulationsare safer compared 
to the conventional forms. A meta-analysis of  randomi-
zed controlled trials (RCTs) concluded that AMG is an 
effective anti-inflammatory drug with an improved GI 
tolerability profile, and lower incidence of GI AEs com-
pared to traditional NSAIDs. The endoscopy scores were 
higher for other NSAIDs than AMG (27.6% versus 21.4%; 
p < 0.05). Likewise, post-treatment severity of gastric and/
or duodenal ulcer was higher in the NSAID group than 
AMG group (14.2% vs. 4.3%; p<0.05) .32    
Practice Recommendation 3
The most common non-modifiable risk factors for NIG 
includeage (>60 years), a prior history of peptic ulcers, 
and complications such asa history of gastrointestinal 
bleeding.
(Consensus: Vote; 65% strongly agree, 33% agree, 2% 
disagree)
Rationale
Age is one of the strongest predictors of NSAID related 
GI complications. A large prospective multicenter study 
in rheumatoid arthritis (RA) patients (N = 2747) found 
that the principal risk factors (p < 0.05) were increasing 
age, a history of NSAID-related ulcer and its complica-
tions, and corticosteroid use.33 Similarly, another study 
reported that age >60 years (OR, 5.52; 95% CI, 4.63–6.60)
and previous history of GI complications (OR, 4.76; 95% 
CI, 4.05–5.59)were associated with an increased risk for 
serious GI AEs.21
Another study reported that the risk for serious 
NSAID induced GI eventswas nearly doubled with each 
of the following factors: a history of previous GI events, 
peptic ulcer, concomitant glucocorticoid treatment, and 
severe arthritis induced disability. Using multiple drugs, 
changing the NSAID, or using high dosesincreasedthe 
risk by at least 6-fold. Age > 65 years and a history of 
cardiovascular disease increased the risk by 2 to 3 fold. 
The presence of multiple risk factors also increased the 
incidence of GI complications during NSAID therapy.34  
Although increasing age is a major risk factor for 
NSAID-induced GI complications, these problems are 
also seen in the pediatric population. In a retrospective, 
multicenter study of Italian children (N = 51) attending 
the emergency unit with GI bleeding following NSAIDs 
use, 62% of patients had endoscopically confirmed 
gastric lesions, 33% had duodenal lesions, and 15% had 
esophageal lesions. Of particular concern, 6% required 
endoscopic hemostasis to control GI bleeding. These 
findings emphasize that children are also vulnerable to 
NSAID-induced gastric complications.35
Practice Recommendation 4
The modifiable risk factors for NIG include concomitant 
use of aspirin and/or other NSAIDs, systemic corticosteroids, 
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anticoagulants/antiplatelet, and selective serotonin reup-
take inhibitors (SSRIs). 
(Consensus: Vote; strongly agree 59%, agree 37%, disagree 
4%)
Rationale
Results from the Italian pharmaco vigilance reporting 
system show that the combined use of LDA and another 
NSAID or use of multiple NSAIDs is associated with an 
increased incidence of GI adverse events.36 Further, the 
Spanish safe prescription recommendations emphasize 
that two or more NSAIDs simultaneously do not increase 
effectiveness but do increase toxicity.37 
A meta-analysis summarized the results from 16 
studies reporting an almost twofold increase in the risk 
of serious GI complications when NSAIDs were used 
concomitantly with corticosteroids compared to NSAIDs 
alone (OR, 1.83; CI, 1.20–2.78).21
A case-control study from the National Health System 
in Spain reported that concomitant use of NSAIDs with 
clopidogrel/ticlopidine (RR, 15.2; 95% CI, 4.1-56.5)oranti-
coagulants (RR, 19.3; 95% CI 8.2–45.3) increased the risk 
of UGI bleeding substantially.38 Similarly, in another case-
control study from the United Kingdom General Practice 
Research Database, combining NSAIDs with clopidogrel 
(RR, 2.93; 95% CI, 1.74–4.93) or warfarin (RR, 4.60; 95% 
CI, 2.77–7.64) was associated with an increased risk of GI 
bleeding.39 Another study found that combined use of 
an NSAID with LDA (OR, 4.3; 95% CI, 1.7–11; p < 0.01) or 
other antiplatelet drugs (OR, 4.9; 95% CI, 1.4-17; p = 0.01) 
was associated with a greater risk of lower GI bleeding 
than when used alone (OR, 2.3; 95% CI, 1.6–3.2; p < 0.01). 
Furthermore,  a combination of NSAIDs was associated 
with a higher risk than use of a single NSAID (OR, 4.9; 
95% CI, 2–12; p < 0.01).40    
A population-based retrospective cohort study 
reported that there  could be up to a 50% increase in the 
risk of GI bleeding with dabigatran compared with war-
farin and a more than the twofold higher risk of bleeding 
with rivaroxaban compared with warfarin.41 Combining 
these newer antiplatelet drugs with NSAIDs carries a 
definite increased GI risk of bleeding.
Selective serotonin reuptake inhibitors may also lead 
to GI bleeding when given with NSAIDs, by impairing 
the metabolism of NSAIDs leading to an increase in their 
blood levels,and also by inhibiting hemostasis.42,43A 
systematic review showed that the RR for UGI bleeding 
from NSAID and SSRI combination compared to use of 
neither drug was 3.3–15.6 and that for GI AEs was 12.4.44 
A case-control study showed a moderate increase in UGI 
risk with concurrent use of SSRIs and NSAIDs when com-
pared to NSAIDs use alone (OR, 1.57; 95% CI, 1.24–1.99) 
and higher increase, when compared to  use of neither 
drug (OR, 4.19; 95% CI, 3.30–5.31).45 Similar results, were 
found in several other studies where the combined use of 
NSAIDs and SSRIs was associated with an OR of about 
4 for GI AEs.46,47 
Practice Recommendation 5
H. pylori infection increases the risk of developing NIG. 
It is suggested that physicians consider the possibility 
of H. pylori infection and treat it, if present, prior to pre-
scribing NSAIDs.
(Consensus: Vote; strongly agree 58%, agree 38%, disagree 
4%)
Rationale
H. pylori infection together with the use of NSAIDs is 
a well-known risk factor that induces gastroduodenal 
mucosal damage and ulcers.48A meta-analysis found that 
NSAIDs and H. pylori infection are not only independent 
risk factors, but they also have a synergistic effect on the 
development of peptic ulcer and ulcer bleeding.49 While 
the risk of ulcer bleeding increased 1.79-fold with H. pylori 
infection and 4.85-fold with NSAID use, the two together 
increased the risk 6.13-fold.49 In a systematic review of 21 
studies (N = 10146), the peptic ulcer was more common 
in NSAID users who were  H. pylori positive (OR, 1.81; 
95% CI, 1.40–2.36).50 Furthermore, in a meta-analysis of 
RCTs, 7.4% of patients developed an ulcer in the H. pylori 
eradicated group compared with 13.3% in the control 
group (OR, 0.43; 95% CI, 0.20–0.93).51A recent retrospec-
tive study of 245 patients taking an NSAID or LDA con-
tinuously for at least 3 months reported that presence 
of H. pylori infection increases the risk of severe gastric 
mucosal injury (OR, 2.0; 95% CI, 1.2–3.5).52
All these studies highlight that NSAIDs and H. pylori 
infection synergistically cause gastric mucosal injury. 
However, H. pylori testing may not be practical for all 
patients especially in the primary care setting.53 Testing 
must be carried out when the patient is prescribed long-
term NSAIDs in areas where H. pylori are common. In 
current practice, H. pylori eradication therapy comprises 
of PPIs and antimicrobials agents, including bismuth 
compounds, clarithromycin, amoxicillin, metronidazole, 
levofloxacin, furazolidone, doxycycline, nitazoxanide, 
andrifabutin.54,55 
Practice Recommendation 6
It is suggested that physicians consider prescribing 
NSAIDs only when indicated.
The prescribing physician should consider patient-
specific risk factors before prescribing NSAIDs.
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(Consensus : Vote; strongly agree 69%, agree 29%, 
disagree 2%)
Rationale
Clinicians must identify NSAIDs use as a risk factor for 
GI complications and initiate preventive treatment. A 
population-based cohort study showed that despite the 
risk of UGI events, guidelines for GPA use were followed 
in less than half of the cases. GPAs were prescribed in 
31.8% of high-risk patients receiving LDA and 48.0% of 
those receiving NSAIDs.56 Similarly, the Canadian Osteo-
arthritis Rx (CANOAR) study examined NSAID use in 
clinical practice in a cohort of PCPs and compared it 
with the osteoarthritis treatment guidelines. Overall, 
58% of the prescriptions were found to be appropriate 
considering the GI risk of the patients.57  Thus, there is an 
opportunity for improvement in implementing strategies 
by adherence to guidelines.56,57
A RCT evaluated a physician education program, 
communicating OA management guidelines in elderly 
patients, which emphasized avoidance of NSAIDs.
Physicians (N = 209) were visited with reminders for a 
re-evaluation of  their patients’ NSAIDs. Brief physician 
educational visits resulted in a 7% (95% CI, 3-11%) reduc-
tion in NSAIDs use without undesirable substitution of 
other medications or detectable worsening of musculo-
skeletal symptoms.58
A Korean observational study of NSAID prescription 
patterns in orthopedic patients highlighted the need 
for better understanding of patient-specific risk factors 
among prescribing physicians. The study showed that, 
despite being identified as high-risk or at very high GI 
risk (by a risk scoring scale), only 51% of patients were 
given a COX-2 selective inhibitor instead of a traditional 
NSAID. Physician’s preference for a particular NSAID 
and not considering a patient’s GI risk factors may expose 
patients to increased risk of NSAID-induced GI compli-
cations.59   
Practice Recommendation 7
It is recommended that the prescribing physician educates 
the patient against self-medication with NSAIDs and the 
importance of regular follow-up, particularly in those on 
long-term and/or high-dose NSAIDs.
(Consensus: Vote; strongly agree 54%, agree 41%, disagree 
4%) 
Rationale
When the prescribed NSAIDs do not adequately control 
pain, patients may  often seek additional OTC NSAIDs.60 
They may not be aware that OTC pain-relief medications 
belong to the same class as their prescribed NSAIDs, 
resulting in high dose NSAID treatment. Patients may 
thus increase their risk of developing GI complications. 
In one study, total 26% of  the participants were users of 
two NSAIDs and had poorer health-related quality of life 
(QoL) compared to those not on high doses of NSAIDs.60 
A cross-sectional study, conducted in the Netherlands, 
assessed the prevalence of OTC-NSAID use in a sample 
of the general population (N = 118) and in a sample of 
patients (N = 264) with a high risk of developing serious 
NSAID-related AEs.2 The results of this study showed 
high and unregulated use of NSAIDs. OTC NSAIDs 
were used by 30% of the general population and 13% 
of the high-risk sample. OTC NSAIDs dose exceeded 
the recommended daily maximum by 9% and 3% in the 
general population and high-risk sample respectively.2 
Proper patient education, is, therefore, of  the utmost 
importance.       
Patients must also be informed about the importance 
of adherence to GPAs. One study evaluated the associa-
tion between adherence to GPA and UGI events among 
NSAID users. Among those who were non-adherent, the 
OR was 2.39 (95% CI, 1.66–3.44) for all UGI events and 
1.89 (95% CI, 1.09–3.28) for UGI bleeding alone, compared 
to those who adhered fully, emphasizing the importance 
of implementing strategies to follow and improve GPA 
adherence.61
Practice Recommendation 8
In patients on long-term NSAID treatment, regular and 
patient-specific monitoring (with due consideration to 
comorbidities, other medications, and the presence of 
all risk factors) is recommended for evidence of gastro-
intestinal bleeding and/or gastrointestinal side-effects. 
(Consensus: Vote; strongly agree 67%, agree 27%, disagree 
4%, strongly disagree 2%) 
Rationale 
Scarpignato and Hunt (2010) suggested that physicians 
should not prescribe NSAIDs before taking a careful 
history and undertaking a physical examination, to 
evaluate patient-specific risks and benefits for NSAID 
therapy.62 Furthermore, in the presence of GI and/or car-
diovascular risk factors, appropriate preventive strategies 
(i.e., COX-2 selective inhibitors and/or PPI use as well 
as the  need for LDA) should be implemented from the 
start of treatment with compliance assessed regularly, 
especially in high-risk patients.62
Practice Recommendation 9
Co-therapy with a PPI is the preferred approach for 
prevention of NIG. Alternatively, a histamine-2 receptor 
antagonist (H2RAs) or misoprostolcan be used. 
(Consensus: Vote; strongly agree 84%, agree 14%, disagree 
2%) 
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Rationale
A systematic reviewand meta-analysis emphasized the 
superiority of PPI therapy over H2RA or placebo in 
reducing mortality among patients with an endoscopi-
cally confirmed high-risk of peptic ulcer bleeding. PPI 
therapy also reduced rates of re-bleeding and the need 
for surgical intervention.63
In a meta-analysis including 10 RCTs (N = 8780), PPIs 
reduced the risk of LDA-associated UGI ulcers (OR = 
0.16; 95% CI, 0.12–0.23) and bleeding (OR = 0.27; 95%CI, 
0.16–0.43) compared with control (placebo, a cytoprotec-
tive agent, or an H2RA).64
A double-blind RCT (OMNIUM study) compared 
omeprazole and misoprostol for NSAID-induced ulcers. 
Although the two drugs were overall equally effective, 
remission rates were better with omeprazole(61% vs 48%; 
p = 0.001). Moreover, omeprazole was better tolerated 
than misoprostol.65
A RCT comparing misoprostol with two doses of lan-
soprazole reported that both drugs were equally effective 
and superior to placebo. After considering the withdraw-
als due to AEs, treatment was deemed successful in 69% 
of patients in each treatment group vs.  35% for placebo.66
A Cochrane review found that misoprostol signifi-
cantly reduced the RR of gastric ulcer by 74% (RR, 0.26; 
95% CI, 0.17–0.39) corresponding to a 12% absolute risk 
reduction.67 The review also reported that, while a stan-
dard dose of H2RA was effective at reducing the risk of 
endoscopic duodenal ulcer (RR = 0.36; 95% CI, 0.18–0.74), a 
double dose was required toreduce the risk of endoscopic 
gastric ulcer (RR = 0.44; 95% CI, 0.26–0.74).67
Practice Recommendation 10
There is no difference in effectiveness between different 
PPIs (esomeprazole, lansoprazole, omeprazole, pantopra-
zole, and rabeprazole) available in the market. All avail-
able PPIs at recommended doseshave similar efficacy in 
reducing the risk of NIG. 
(Consensus: Vote; strongly agree 76%, agree 24%) 
Rationale
Few head-to-head studies are comparing the different 
PPIs in the   managementof NIG. However, the available 
data suggest that all PPIs are essentially equivalentin the 
management of NIG. A randomized, double-blind study 
(N = 595) to compare pantoprazole (20 mg OD and 40 
mg OD) withomeprazole (20 mg OD) for the prevention 
of GI lesions associated with NSAIDs found that both 
PPIs were similarly effective (remission rates for lack of 
“therapeutic failure” were 90%, 93%, and 89%, and for 
lack of  “endoscopic failure” were 91%, 95%, and 93% (for 
pantoprazole 20 mg OD, pantoprazole 40 mg OD, and 
omeprazole 20 mg OD, respectively).68  
A systematic review comparing the efficacy of dif-
ferent available PPIs found that for symptom relief in 
gastroesophageal reflux disease lansoprazole was faster 
than omeprazole, and esomeprazole was faster than both 
lansoprazole and omeprazole. However, none of these-
drugs was found to be superior over the other.69 
A few novels  or immediate-release formulations of 
PPIs have also been studied.70 The immediate-release 
omeprazole (Zegerid®, Omez-Insta®) are associated with 
faster absorption of omeprazole, the  more rapid onset 
of anti-secretory activity, and a slightly longer duration 
of acid suppression. This formulation is not food depen-
dent and provides dosing flexibility which is considered 
apt for suppressing nocturnal gastric acid secretion.71 
Immediate-release omeprazole has also shown superi-
ority over once daily dosing of delayed-release PPIs in 
control of nocturnal gastric acidity.72 Dexlansoprazole 
is a PPI with adual delayed-release formulation, which 
produces a dual-peak pharmacokinetic profile unlike 
the single peak profile of the first generation or delayed 
release PPIs. Thus, dexlansoprazole maintains therapeu-
tic plasma drug concentrations longer than lansoprazole 
and other PPIs.73 
Practice Recommendation 11
It is suggested that physicians consider continued pro-
phylaxis with a PPI when NSAIDs are prescribed.
(Consensus: Vote; strongly agree 69%, agree 31%) 
Rationale
In a large international multicenter study (N = 610), both 
omeprazole and misoprostol improved QoL in chronic 
NSAID users with NSAID-associated gastroduodenal 
lesions. However, omeprazole relieved gastrointestinal 
symptoms better than misoprostol. Hence, it is appro-
priate to co-prescribe a PPI in this patient group for pro-
phylaxis as long as NSAIDs are prescribed and taken.74
Long-term PPI treatment is associated with better-
outcomes in patients continuing NSAID therapy. A large 
RCT in OA and RA patients compared omeprazole with 
ranitidine in the prevention of gastric and duodenal 
ulcers. Omeprazole healed and prevented ulcers more 
effectively than ranitidine over 8 weeks of the study. 
During the subsequent 6-month maintenance treatment, 
72% and 59% of patients were in remission in the omepra-
zole and ranitidine groups respectively. Relapses were 
more common with ranitidine than with omeprazole.75
In long-term NSAID users, a PPI can substantially 
reduce the occurrence of GI complications. A 3-month 
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studyto evaluate omeprazole 20 mg every morning as 
primary prophylaxis against NSAID-induced ulcer 
and dyspepsia, found that the estimated probability 
of remaining symptom-free for 6 months for patients 
taking omeprazole was 0.78 compare d to 0.53 for placebo 
(p = 0.004).76 Thus, continuing a PPI is important in the 
management of NIG. Although long-term PPIs could 
be associated with some AEs, in patients with a clear 
indication for the PPI, the risk-benefit ratio favors PPI 
use.43
Practice Recommendation 12
The following clinical presentations in a patient taking an 
NSAID to raise  the suspicion of NIG: abdominal cramps/
pain, dyspepsia, nausea, and vomiting.
In patients with pre-existing risk factors for gas-
tropathy, it is suggested that the physician maintain 
a high index of suspicion of onset of NSAID-induced 
gastropathy in patients on NSAID therapy developing 
such symptoms. 
(Consensus: Vote; strongly agree 43%, agree 40%, disagree 
9%, and strongly disagree 9%)
Rationale 
Upper GI symptoms including dyspepsia, heart-
burn, bloating or cramping, nausea, and vomiting are 
reported in up to 40% of patients taking NSAIDs.77 
However, in 50 to 60% NSAIDs users, GI complications 
may be clinically asymptomatic.78 Hence, close monitor-
ing is advisable forall patients on long-term NSAIDs, 
particularly those with the presence of one or more risk 
factors. 
Practice Recommendation 13
It is suggested that to determine the risk, physicians take 
a careful history andperform necessary laboratory tests 
when starting NSAID treatment. 
If a patient presents with a history, or clinical symp-
toms and signs suggesting NSAID-related GI problems, 
the PCP should consider referring the patient to a special-
ist for further management.
(Consensus: Vote; strongly agree 38%, agree 54%, disagree 
16%, and strongly disagree 2%)
Rationale
Standard approaches for diagnosing NIG include 
identification of high-risk populations; history, clinical 
presentation, and examination of the patient; tests for 
H. pylori infection in suspected cases; and hemoglobin 
and hematocrit tests. Upper GI endoscopy is required to 
confirm the diagnosis.79
Practice Recommendation 14
While PPIs are the preferred drugs, some choice of GPA 
(in treatment doses) is recommended for patients diag-
nosed with NIG.
(Consensus: Vote; strongly agree 40%, agree 40%, disagree 
17%, and strongly disagree 2%) 
Rationale
Several studies have highlighted the efficacy of PPIs 
in the treatment of LDA- and NSAID-induced GI 
injury.63,64, 80-82 Evidence also indicates that PPIs are supe-
rior to other GPAs.63-65,74,75  Therefore, PPIs remain the 
preferred treatment. Nevertheless, other GPAs, includ-
ing H2RAs and misoprostol, have also demonstrated 
effectiveness in the treatment of NIG,66,67,83,84 and may 
be considered when PPIs cannot be prescribed.
Practice Recommendation 15
A fixed-dose combination (FDC) of an NSAID and a GPA 
is not recommended in patients with NIG.
(Consensus: Vote; strongly agree 59%, agree 28%, disagree 
13%) 
Rationale
The ketoprofen-omeprazole FDC was the first NSAID 
GPA combination to be approved.85 Other commonly 
used FDCs include ibuprofen-famotidine and naproxen-
esomeprazole.86,87 Although FDCs are believed to be asso-
ciated with better compliance;  sufficient clinical evidence 
is not available to support their superiority regarding 
efficacy and safety.86,87 Furthermore, the high-cost of FDC 
makes prescription difficult in long-term users, such as 
patients with OA.    
Boxes 1 and 2 list the recommendations for doctors 
in the treatment of NIG for highrisk and moderate risk 
patients respectively.
CONCLUSION
NSAIDs are the most widely used drugs for controlling 
pain and inflammation. Easy availability (as OTC drugs) 
and good efficacy of these drugs increase their use. 
However, the gastrointestinal complications, particularly 
gastropathy, remain a matter of concern for the prescrib-
ing physician. The risks of developing gastropathy further 
increase with high-dose, long-term, or inappropriate 
use of NSAIDs especially in the elderly. Hence, recom-
mendations are necessary to guide a PCP in making safe 
and sensible use of NSAIDs and to minimize the risk 
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Box 1: Recommendations for doctors–high risk patients
 1. Document patient's history and carry out necessary 
laboratory investigations before starting any treatment 
 2. For high-risk patients, avoid NSAIDs and use alternate 
management strategies like physiotherapy and/or exercise 
to ease pain and inflammation in diseases like OA
 3. Consider prescribing low doses and shorter durations 
for diseases that require instant relief (headache, 
dysmenorrhea, post-operative pain)
 4. Consider pulse therapy – prescribing large doses NSAIDs 
in an intermittent manner to enhance the therapeutic effect 
and reduce the GI complications/other adverse events in 
chronic diseases
 5. Avoid prescribing NSAIDs with other drugs (SSRIs, anti-
platelet drugs, corticosteroids)
 6. Inform the patient that NSAIDs can be taken “as required" 
and generally do not have a fixed schedule
 7. Prefer selective COX-2 inhibitors like coxibs or safer drugs 
like amtolmentinguacyl over conventional NSAIDs
 8. Prescribe double dose of gastroprotective agents like PPIs in 
patients undergoing long-term (>30 days) NSAID treatment
 9. Prescribe a single dose of PPI (up to 30 days) in patients 
undergoing NSAID treatment
 10. Perform periodic assessment of patients on long-term 
NSAID therapy for early identification of signs/symptoms 
of gastropathy
Abbreviations: COX-2, cyclooxygenase-2; GI, gastrointestinal; NSAID, 
non-steroidal anti-inflammatory drug; OA, osteoarthritis; SSRI, selective 
serotonin reuptake inhibitor
of gastropathy. The Consensus Group recommends the 
use of NSAIDs only as and when indicated. Associated 
risk factors and a risk profile of the patient is important 
and should be determined before prescribing NSAIDs. 
Additionally, physicians are encouraged to take time to 
educate their patients about the safe use of NSAIDs prop-
erly, to avoid dose creep, and not combine their prescribed 
drugs with OTC medications without prior discussion 
with their physician. Furthermore, risk monitoring of 
patients undergoing long-term NSAID treatment and co-
therapy with a GPA usually a PPI is also recommended. 
The consensus group emphasizes the importance of the 
patient’s age, history, clinical presentation, and presence 
of H. pylori infection for timely management of NIG; and 
the need to develop clinical strategies to ensure GI safety 
for patients undergoing NSAID treatment.  
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Box 2: Recommendations for doctors–moderate risk patients 
 1 Document patient’s history and carry out necessary 
laboratory investigations before starting any treatment
 2. Consider prescribing topical NSAIDs over oral NSAIDs in 
patients experiencing mild pain like muscle pain, or low back 
pain
 3 Initiate prophylactic therapy with PPI (e.g. Omeprazole 20 
mg once daily) to reduce the risk of gastropathy
 4. Consider H. pylori eradication in case it was diagnosed, and 
eradication therapy not given
 5. Include an antacid in the drug regimen as antacids neutralize 
existing stomach acid and can provide rapid pain relief
 6. Consider probiotic supplement (containing Lactobacillus 
acidophilus). Probiotics or “friendly” bacteria may help 
maintain a balance in the digestive system between good  
and harmful bacteria
 7. Suggest a multivitamin daily to improve digestive health 
(e.g. multivitamins containing the antioxidant vitamins A, C, 
E, the B vitamins, and trace minerals, such as magnesium, 
calcium, zinc, and selenium)
 8. Guide patients to avoid self-medication, high dose 
unregulated use of NSAIDs, and to never combine OTC 
medications without consultation
 9. Counsel the patients well and educate them on the signs and 
symptoms of gastropathy so that they can reach for help at 
the earliest
 10. Suggest the patients to visit regularly so that the need for 
further treatment with NSAIDs can be reviewed
Abbreviations: COX-2, cyclooxygenase-2; GI, gastrointestinal; NSAID, 
non-steroidal anti-inflammatory drug; OA, osteoarthritis; OTC, over-the-
counter; SSRI, selective serotonin reuptake inhibitor
Contd...
International Consensus on NSAIDs Gastropathy
Euroasian Journal of Hepato-Gastroenterology, July-December 2018;8(2):148-160 157
EJOHG
Participant Name Country
Mikhail Sheviakov Russia
Tatiana Sviridova Russia
Oksana Pozdniakova Russia
Elina Petrova Russia
Svetlana Turkina Russia
Elena Vyuchnova Russia
AimanSarsenbaeva Russia
Irina Kozlova Russia
Aleksandr Stepchenko Russia
Oleg Mironchev Russia
Alexey Okhlobystin Russia
Tatiana Iankovaia Russia
Elena Li Russia
Inna Putintseva Russia
Zarina Galeeva Russia
Sergei Alekseenko Russia
Elena Miguskina Russia
EmiliyaYakovenko Russia
Elena Kashkina Russia
Leonid Lazebnik Russia
Natalia Bakulina Russia
Victor Pasechnikov Russia
Dmitry Bordin Russia
Anell Meyer South Africa
Reidwaan Ally South Africa
Bilal Bobat South Africa
Vasudevan Naidoo South Africa
Fritz Potgieter South Africa
Monique Marais South Africa
Hitendrakumar Bhaga South Africa
Sandie Thomson South Africa
Yurii Stepanov Ukraine
Olha Bondarenko Ukraine
Andriy Dorofyeyev Ukraine
Abror Khamraev Uzbekistan
Feruza Khamrabaeva Uzbekistan
REFERENCES
 1. Singh G. Gastrointestinal complications of prescription and 
over-the-counter nonsteroidal anti-inflammatory drugs: a 
view from the ARAMIS database. Arthritis, Rheumatism, 
and Aging Medical Information System. Am J Ther 2000 
Mar;7(2):115-121.
 2. Koffeman AR, Valkhoff VE, Çelik S, W't Jong G, Sturkenboom 
MC, Bindels PJ, et al. High-risk use of over-the-counter non-
steroidal anti-inflammatory drugs: a population-based cross-
sectional study. Br J Gen Pract 2014 Apr;64(621):e191-198.
 3. Peura DA. Gastrointestinal safety and tolerability of nonse-
lective nonsteroidal anti-inflammatory agents and cyclooxy-
genase-2-selective inhibitors. Cleve Clin J Med 2002;69(Suppl 
1):SI31-139. 
 4. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonste-
roidal antiinflammatory drugs: an update of gastrointestinal, 
cardiovascular and renal complications. J Pharm Pharm Sci 
2013;16(5):821-847.
 5. Lassen A, Hallas J, Schaffalitzky de Muckadell OB. Compli-
cated and uncomplicated peptic ulcers in a Danish county 
1993-2002: a population-based cohort study. Am J Gastroen-
terol 2006 May;101(5):945-953.
 6. Chatterjee S, Dureja GP, Kadhe G, Mane A, Phansalkar AA, 
Sawant S, et al. Cross-Sectional Study for Prevalence of Non-
Steroidal Anti-Inflammatory Drug-Induced Gastrointestinal, 
Cardiac and Renal Complications in India: Interim Report. 
Gastroenterology Res 2015 Aug;8(3-4):216-221.
 7. Straube S, Tramèr MR, Moore RA, Derry S, McQuay HJ. 
Mortality with upper gastrointestinal bleeding and perfora-
tion: effects of time and NSAID use. BMC Gastroenterol 2009 
Jun;9(1):41.
 8. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo 
R, Eriksson, et al. Prevalence and incidence of gastroduodenal 
ulcers during treatment with vascular protective doses of 
aspirin. Aliment Pharmacol Ther 2005 Nov;22(9):795-801.
 9. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: 
Importance of cyclooxygenase inhibition and gastric hyper-
motility. World J Gastroenterol 2012 May;18(18):2147-2160.
 10. Unified Clinical Protocol for Primary and Secondary Medical 
Care Peptic Ulcer of Stomach and Duodenum in Adults, 
Ukraine,  2014  Sep. Available at:  http://mtd.dec.gov.ua/
images/dodatki/2014_613_PeptVyrazka_12paloi/2014_613y
kpmd_PeptVyr.pdf.  
 11. Russian gastroenterological association clinical guidelines on 
diagnosis and treatment of NSAIDs-associated erosive and 
ulcerative lesions of the stomach and duodenum;2014. Avail-
able at: http://www.gastro.ru/userfiles/R_npvp_2014_6.pdf.
 12. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman 
DJ, Clark CB, Furberg CD,  et al. ACCF/ACG/AHA. ACCF/
ACG/AHA 2010 Expert Consensus Document on the Con-
comitant Use of Proton Pump Inhibitors and Thienopyridines: 
A Focused Update of the ACCF/ACG/AHA 2008 Expert Con-
sensus Document on Reducing the Gastrointestinal Risks of 
Antiplatelet Therapy and NSAID Use: a report of the American 
College of Cardiology Foundation Task Force on Expert Con-
sensus Documents. Circulation 2010 Dec;122(24):2619-2633. 
 13. Lanza FL, Chan FK, Quigley EM. Practice Parameters Commit-
tee of the American College of Gastroenterology. Guidelines 
for prevention of NSAID-related ulcer complications. Am J 
Gastroenterol 2009 Mar;104(3):728-738.
 14. NICE Guidelines: Acute upper gastrointestinal bleeding in 
over 16s: management. Available at: https://www.nice.org.
uk/guidance/cg141.
 15. Unified Clinical Protocol for Primary Medical Care Dyspepsia, 
Ukraine [August2012]. Available at: http://mtd.dec.gov.ua/
images/dodatki/2012_600/19_07_2012_ykpmd.pdf. 
 16. Rostom A, Moayyedi P, Hunt R. Canadian Association of 
Gastroenterology Consensus Group. Canadian consensus 
guidelines on long-term nonsteroidal anti-inflammatory drug 
Contd...
Richard Hunt et al.
158
therapy and the need for gastroprotection: benefits versus 
risks. Aliment PharmacolTher 2009 Mar;29(5):481-496.
 17. Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, 
Hunt RH, International NSAID Consensus Group. Safe pre-
scribing of non-steroidal anti-inflammatory drugs in patients 
with osteoarthritis--an expert consensus addressing benefits 
as well as gastrointestinal and cardiovascular risks. BMC Med 
2015 Mar;13:55.
 18. Dalkey N, Helmer O. An Experimental Application of the 
DELPHI Method to the Use of Experts. Management Science. 
1962 July;9(3):458-467
 19. Hsu Chia-Chien, Sandford BA. The Delphi Technique: Making 
Sense of Consensus. Practical Assessment, Research & Evalu-
ation. 2007 Aug;12(10):1-8. 
 20. Lanas A, Boers M, Nuevo J. Gastrointestinal events in 
at-risk patients starting non-steroidal anti-inflammatory 
drugs (NSAIDs) for rheumatic diseases: the EVIDENCE 
study of European routine practice. Ann Rheum Dis 2015 
Apr;74(4):675-681.
 21. Schaffer D, Florin T, Eagle C, Marschner I, Singh G, Grobler 
M, et al. Risk of serious NSAID-related gastrointestinal events 
during long-term exposure: a systematic review. Med J Aus. 
2006 Nov;185(9):501-506.
 22. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. 
Gastrointestinal damage associated with the use of non-
steroidal anti-inflammatory drugs. N Engl J Med 1992; Sep 
327(11):749-754.
 23. Garcı´ aRodrı´ guez LA, Barreales Tolosa L. Risk of upper gas-
trointestinal complications among users of traditional NSAIDs 
and COXIBs in the general population. Gastroenterology 2007 
Feb;132(2):498-506.
 24. Hernández Díaz S, García Rodríguez LA. Association 
between nonsteroidal anti-inflammatory drugs and upper 
gastrointestinal tract bleeding/perforation. An overview of 
epidemiologic studies published in the 1990s. Arch Intern 
Med 2000 Jul;160(14):2093-2099.
 25. García Rodríguez LA, Hernández-Díaz S. Relative risk of 
upper gastrointestinal complications among users of acet-
aminophen and nonsteroidal anti-inflammatory drugs. 
Epidemiology 2001 Sep;12(5):570-576.
 26. Tarone RE, Blot WJ, McLaughlin JK. Nonselective nonaspirin 
nonsteroidal anti-inflammatory drugs and gastrointestinal 
bleeding: relative and absolute risk estimates from recent 
epidemiologic studies. Am J Ther 2004 Jan-Feb;11(1):17- 
25.
 27. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, 
Eriksson B, et al.  Prevalence and incidence of gastroduodenal 
ulcers during treatment with vascular protective doses of 
aspirin. Aliment Pharmacol Ther 2005 Nov;22(9):795-801.
 28. Derry S, Loke YK. Risk of gastrointestinal haemorrhage 
with long term use of aspirin: meta-analysis. BMJ 2000 
Nov;321(7072):1183-1187.
 29. Makris UE, Kohler MJ, Fraenkel L. Adverse Effects (AEs) of 
Topical NSAIDs in Older Adults with Osteoarthritis (OA): 
a Systematic Review of the Literature. J Rheumatol 2010 
Jun;37(6):1236-1243.
 30. Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo 
C, Fourrier-Reglat A, Nicotra F, et al. Individual NSAIDs and 
upper gastrointestinal complications: a systematic review and 
meta-analysis of observational studies (the SOS project). Drug 
Saf 2012 Dec;35(12):1127-1146.
 31. Huang JQ, Sridhar S, Hunt RH. Gastrointestinal safety 
profile of nabumetone: a meta-analysis. Am J Med 1999 
Dec;107(6A):55S-61S; discussion 61S-64S.
 32. Garg A, Shoeb A, Moodahadu LS, Sharma A, Gandhi A, Akku 
S. Amtolmeti: A Reappraisal of NSAID with Gastroprotection. 
Arthritis 2016;2016:7103705.
 33. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal 
anti-inflammatory drug- associated gastropathy: incidence 
and risk factor models. Am J Med 1991 Sep;91(3):213-222. 
 34. Koch M, Dezi A, Tarquini M, Capurso L. Prevention of non-
steroidal anti-inflammatory drug-induced gastrointestinal 
mucosal injury: risk factors for serious complications. Dig 
Liver Dis 2000 Nov;32(20):138-151.
 35. Cardile S, Martinelli M, Barabino A, Gandullia P, Oliva S, 
Nardo GD,  et al. Italian survey on non-steroidal anti-inflam-
matory drugs and gastrointestinal bleeding in children. World 
J Gastroenterol 2016 Feb;22(5):1877-1883.
 36. Rafaniello C, Ferrajolo C, Sullo MG, Sessa M, Sportiello L, 
Balzano A, et al. Risk of gastrointestinal complications asso-
ciated to NSAIDs, low-dose aspirin and their combinations: 
Results of a pharmacovigilance reporting system. Pharmacol 
Res 2016 Feb;104:108-114.
 37. Lanas A, Benito P, Alonso J, Hernández-Cruz B, Barón-Esquiv-
ias G, Perez-Aísa Á, et al.  Safe prescription recommendations 
for non-steroidal anti-inflammatory drugs: consensus docu-
ment ellaborated by nominated experts of three scientific asso-
ciations (SER-SEC-AEG). ReumatolCli. 2014 Mar-Apr;10(2): 
68-84.
 38. Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu 
F, González-Pérez A,et al. Risk of upper gastrointestinal ulcer 
bleeding associated with selective cyclo-oxygenase-2 inhibi-
tors, traditional non-aspirin non-steroidal anti-inflammatory 
drugs, aspirin and combinations. Gut 2006 Dec;55(12):1731-
1738.
 39. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug inter-
actions between antithrombotic medications and the risk of 
gastrointestinal bleeding. CMAJ 2007 Aug;177(4):347-351.
 40. Nagata N, Niikura R, Aoki T, Shimbo T, Kishida Y, Sekine K, et 
al. Lower GI bleeding risk of nonsteroidal anti-inflammatory 
drugs and antiplatelet drug use alone and the effect of com-
bined therapy. GastrointestEndosc 2014 Dec;80(6):1124-1131.
 41. Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk 
of gastrointestinal bleeding associated with oral anticoagu-
lants: population based retrospective cohort study. BMJ 2015 
Apr;350:h1585.
 42. Halperin D, Reber G. Influence of antidepressants on hemo-
stasis. Dialogues Clin Neurosci 2007;9(1):47-59.
 43. Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-
FIMMG Group; Italian Society of Pharmacology, the Italian 
Association of Hospital Gastroenterologists, and the Italian 
Federation of General Practitioners. Effective and safe proton 
pump inhibitor therapy in acid-related diseases - A position 
paper addressing benefits and potential harms of acid sup-
pression. BMC Med 2016 Nov;14(1):179.
 44. Mort JR, Aparasu RR, Baer RK. Interaction between selective 
serotonin reuptake inhibitors and nonsteroidal antiinflamma-
tory drugs: review of the literature. Pharmacotherapy 2006 
Sep;26(9):1307-1313.
 45. Helin-Salmivaara A, Huttunen T, Grönroos JM, Klaukka T, 
Huupponen R. Risk of serious upper gastrointestinal events 
with concurrent use of NSAIDs and SSRIs: a case-control 
study in the general population. Eur J Clin Pharmacol 2007 
Apr;63(4):403-408.
 46. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontia-
dis GI. Risk of upper gastrointestinal bleeding with selective 
serotonin reuptake inhibitors with or without concurrent 
International Consensus on NSAIDs Gastropathy
Euroasian Journal of Hepato-Gastroenterology, July-December 2018;8(2):148-160 159
EJOHG
nonsteroidal anti-inflammatory use: a systematic review 
and meta-analysis. Am J Gastroenterol 2014 Jun;109(6):811- 
819.
 47. Oka Y, Okamoto K, Kawashita N, Shirakuni Y, Takagi T. Meta-
analysis of the risk of upper gastrointestinal hemorrhage with 
combination therapy of selective serotonin reuptake inhibitors 
and non-steroidal anti-inflammatory drugs. Biol Pharm Bull 
2014;37(6):947-953.
 48. Sostres C, Gargallo CJ, Lanas A. Interaction between Helico-
bacter pylori infection, nonsteroidal anti-inflammatory drugs 
and/or low-dose aspirin use: old question new insights. World 
J Gastroenterol 2014 Jul;20(28):9439-9450.
 49. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori 
infection and non-steroidal anti-inflammatory drugs in peptic-
ulcer disease: a meta-analysis. Lancet 2002 Jan;359(9300):14- 
22.
 50. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. 
Effects of Helicobacter pylori and nonsteroidal anti-inflam-
matory drugs on peptic ulcer disease: a systematic review. 
Clin Gastroenterol Hepatol 2006 Feb;4(2):130-142.
 51. Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-analysis: 
role of Helicobacter pylori eradication in the prevention of 
peptic ulcer in NSAID users. Aliment PharmacolTher 2005 
Jun;21(!2):1411-1418.
 52. Kono Y, Okada H, Takenaka R, Miura K, Kanzaki H, Hori K, 
et al. Does Helicobacter pylori Exacerbate Gastric Mucosal 
Injury in Users of Nonsteroidal Anti-Inflammatory Drugs? 
A Multicenter, Retrospective, Case-Control Study. Gut Liver 
2016 Jan;10(1):69-75.
 53. Pounder RE. Helicobacter pylori and NSAIDs--the end of the 
debate? Lancet 2002 Jan;359(9300):3-4.
 54. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers 
EJ, Axon AT, et  al. European Helicobacter and Microbiota 
Study Group and Consensus panel. Management of Helico-
bacter pylori infection-the Maastricht V/Florence Consensus 
Report. Gut 2017 Jan;66(1):6-30.
 55. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, 
Hunt RH, et al. The Toronto Consensus for the Treatment of 
Helicobacter pylori Infection in Adults. Gastroenterology 2016 
Jul;151(1):51-69.e14.
 56. Warlé-van Herwaarden MF, Koffeman AR, Valkhoff VE, 't Jong 
GW, Kramers C, Sturkenboom MC, et al. Time-trends in the 
prescribing of gastroprotective agents to primary care patients 
initiating low-dose aspirin or non-steroidal anti-inflammatory 
drugs: a population-based cohort study. Br J Clin Pharmacol 
2015 Sep;80(3):589-598.
 57. Sebaldt RJ, Petrie A, Goldsmith CH, Marentette MA. Appro-
priateness of NSAID and Coxib prescribing for patients with 
osteoarthritis by primary care physicians in Ontario: results 
from the CANOAR study. Am J Manag Care 2004;10(11):742-
750.
 58. Ray WA, Stein CM, Byrd V, Shorr R, Pichert JW, Gideon P, 
et al. Educational program for physicians to reduce use of 
non-steroidal anti-inflammatory drugs among community-
dwelling elderly persons: a randomized controlled trial. Med 
Care 2001;39(5):425-435.
 59. Lee SH, Han CD, Yang IH, Ha CW. Prescription Pattern of 
NSAIDs and the Prevalence of NSAID-induced Gastrointes-
tinal Risk Factors of Orthopaedic Patients in Clinical Practice 
in Korea. J Korean Med Sci 2011 Apr;26(4):561-567.
 60. Kovac SH, Saag KG, Curtis JR, Allison J. Association of health-
related quality of life with dual use of prescription and over-
the-counter nonsteroidal antiinflammatory drugs. Arthritis 
Rheum 2008 Feb;59(2):227-233.
 61. van Soest EM, Valkhoff VE, Mazzaglia G, Schade R, Molokhia 
M, Goldstein JL,  et al. Suboptimal gastroprotective coverage 
of NSAID use and the risk of upper gastrointestinal bleed-
ing and ulcers: an observational study using three European 
databases. Gut 2011;60:1650-1659.
 62. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory 
drug-related injury to the gastrointestinal tract: clinical 
picture, pathogenesis, and prevention. Gastroenterol Clin 
North Am 2010 Sep;39(3):433-464.
 63. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney 
B, Howden CW,  et al. Systematic reviews of the clinical effec-
tiveness and cost-effectiveness of proton pump inhibitors in 
acute upper gastrointestinal bleeding. Health Technol Assess 
2007 Dec;11(51):iii-iv, 1-164.
 64. Mo C, Sun G, Lu ML, Zhang L, Wang YZ, Sun X,  et al. Proton 
pump inhibitors in prevention of low-dose aspirin-associated 
upper gastrointestinal injuries. World J Gastroenterol 2015 
May;21(17):5382-5392. 
 65. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun 
A, Swannell AJ, Yeomans ND. Omeprazole compared with 
misoprostol for ulcers associated with nonsteroidal anti-
inflammatory drugs. Omeprazole versus Misoprostol for 
NSAID-induced Ulcer Management (OMNIUM) Study Group. 
N Engl J Med 1998 Mar;338(11):727-734.
 66. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, 
Lukasik NL, et al. Ulcer prevention in long-term users of non-
steroidal anti-inflammatory drugs: results of a double-blind, 
randomized, multicenter, active- and placebo-controlled 
study of misoprostol vs. lansoprazole. Arch Intern Med 2002 
Jan;162(2):169-175.
 67. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, 
McGowan J. Prevention of NSAID-induced gastroduodenal 
ulcers. Cochrane Database Syst Rev 2002;4:CD002296.
 68. Regula J, Butruk E, Dekkers CP, de Boer SY, Raps D, Simon L, 
et al. Prevention of NSAID-associated gastrointestinal lesions: 
a comparison study pantoprazole versus omeprazole. Am J 
Gastroenterol 2006;101(8):1747-1755.
 69. Vakil N, Fennerty MB. Direct comparative trials of the efficacy 
of proton pump inhibitors in the management of gastro-
oesophageal reflux disease and peptic ulcer disease. Aliment 
Pharmacol Ther 2003 Sep;18(6):559-568.
 70. Howden CW. Review article: immediate-release proton-pump 
inhibitor therapy--potential advantages Aliment Pharmacol-
Ther 2005 Dec;22 Suppl 3:25-30.
 71. Castell D. Review of immediate-release omeprazole for the 
treatment of gastric acid-related disorders. Expert OpinPhar-
macother 2005 Nov;6(14):2501-2510.
 72. Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Compari-
son of the effects of immediate-release omeprazole powder 
for oral suspension and pantoprazole delayed-release tablets 
on nocturnal acid breakthrough in patients with symptomatic 
gastro-oesophageal reflux disease. Aliment Pharmacol Ther 
2005 Jun;21(12):1467-1474.
 73. Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual 
delayed release formulation of dexlansoprazole MR, a novel 
approach to overcome the limitations of conventional single 
release proton pump inhibitor therapy. Aliment Pharmacol-
Ther 2009 May;29(9):928-937.
 74. Yeomans N, Wilson I, Långström G, Hawkey C, Naesdal J, 
Walan A, et al. Quality of life in chronic NSAID users: a com-
Richard Hunt et al.
160
parison of the effect of omeprazole and misoprostol. Scand J 
Rheumatol 2001;30(6):328-334. 
 75. Yeomans ND, Tulassay Z, Juhasz L, Rácz I, Howard JM, van 
Rensburg CJ, et al. A comparison of omeprazole with raniti-
dine for ulcers associated with nonsteroidal anti-inflamma-
tory drugs. Acid Suppression Trial: Ranitidine vs. Omeprazole 
for NSAID-associated Ulcer Treatment (ASTRONAUT) Study 
Group. N Engl J Med 1998 Mar;338(11):719-726.
 76. Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, 
Thomson JM, et al. Primary gastroduodenal prophylaxis with 
omeprazole for non-steroidal anti-inflammatory drug users. 
Aliment PharmacolTher 1998 Feb;12(2):135-140.
 77. Brun J, Jones R. Non-steroidal anti-inflammatory drug-
associated dyspepsia: the scale of the problem. Am J Med 
2001 Jan;110(1A):12S-13S.
 78. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory 
drugs and life threatening complications of peptic ulceration. 
Gut1987 May;28(5):527-532.
 79. Schellack N. An overview of gastropathy induced by non-
steroidal anti-inflammatory drugs. S Afr Pharm J 2012;79(4): 
12-18.
 80. Sugano K, Choi MG, Lin JT, Goto S, Okada Y, Kinoshita 
Y, et al. LAVENDER Study Group. Multinational, double-
blind, randomised, placebo-controlled, prospective study of 
esomeprazole in the prevention of recurrent peptic ulcer in 
low-dose acetylsalicylic acid users: the LAVENDER study. 
Gut 2014;63(7):1061-1068.
 81. Scheiman JM, Lanas A, Veldhuyzen van Zanten S, Baldycheva 
I, Svedberg LE, Nagy P. Effect of esomeprazole on gastro-
duodenal erosions in patients at increased gastrointestinal 
risk treated with low-dose acetylsalicylic acid: a post-hoc 
analysis of the OBERON trial. Int J Cardiol 2015 Mar;182:500-
502.
 82.  Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons 
D.The effectiveness of five strategies for the prevention of 
gastrointestinal toxicity induced by non-steroidal anti-inflam-
matory drugs: systematic review.BMJ 2004 Oct;329(7472): 
948.
 83. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, 
Cot trell J, et al. Famotidine for the prevention of gastric and 
duodenal ulcers caused by nonsteroidal antiinflammatory 
drugs. N Engl J Med 1996 May;334(22):1435-1439.
 84. Van Groenendael JH, Markusse HM, Dijkmans BA, Breed-
veld FC. The effect of ranitidine on NSAID related dyspeptic 
symptoms with and without peptic ulcer disease of patients 
with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 
1996 Sep;15(5):450-456.
 85. Gigante A, Tagarro I. Non-steroidal anti-inflammatory 
drugs and gastroprotection with proton pump inhibitors: 
a focus on ketoprofen/omeprazole. Clin Drug Investig 2012 
Apr;32(4):221-233.
 86. Weinblatt, Michael E, Genovese, Mark C, Kivitz, Alan J, et 
al. Efficacy, Safety And Tolerability Of HZT-501, Including 
Users Of Low-Dose Aspirin, A Single-Tablet Combina-
tion Of Ibuprofen-Famotidine: Results Of Two Phase 3 
Trials. [abstract] Arthritis Rheum 2010 Oct;62(10)(Suppl 
10):945.
 87. Sostek MB, Fort JG, Estborn L, Vikman K. Long-term safety 
of naproxen and esomeprazole magnesium fixed-dose 
combination: phase III study in patients at risk for NSAID-asso-
ciated gastric ulcers. Curr Med Res Opin 2011 Apr;27(4):847-
854.
View publication stats
